Glucagon-like peptide-1 receptor agonists but not dipeptidyl peptidase-4 inhibitors reduce alcohol intake
Click on the JSmol tab to take a closer look at how GLP-1 (PDB 6X18), semaglutide (PDB 7KI0), tirzepatide (PDB 7FIM), and orforglipron (PDB 6XOX) are able to stabilize the active form of the GLP-1 receptor, and compare these structures to that of the inactive GLP-1 receptor (PDB 6LN2)
Once you stop taking the medication, your appetite and hunger hormones rebound, leading to: A return of appetite and food cravings Reduced satiety (feelings of satisfaction/fullness)
Do not wait until you feel bad to start managing side effects
Diarrhea results from altered gut motility, the movement of contents through the intestine, which GLP-1 medications affect along the entire digestive tract
The FDA has declared there are no longer shortages of tirzepatide and semaglutide, but some compounding pharmacies continue to produce it, most often for telehealth clinics